

# Bridgette M Collins-Burow

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7200056/publications.pdf>

Version: 2024-02-01

21  
papers

297  
citations

933447

10  
h-index

888059

17  
g-index

23  
all docs

23  
docs citations

23  
times ranked

494  
citing authors

#	ARTICLE	IF	CITATIONS
1	Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 593-604.	2.5	85
2	Pharmacological, Mechanistic, and Pharmacokinetic Assessment of Novel Melatonin-Tamoxifen Drug Conjugates as Breast Cancer Drugs. <i>Molecular Pharmacology</i> , 2019, 96, 272-296.	2.3	30
3	Obesity-Altered Adipose Stem Cells Promote ER+ Breast Cancer Metastasis through Estrogen Independent Pathways. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1419.	4.1	29
4	A novel patient-derived xenograft model for claudin-low triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 381-390.	2.5	19
5	Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model. <i>BMC Cancer</i> , 2019, 19, 205.	2.6	19
6	Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model. <i>Oncoscience</i> , 2018, 5, 99-108.	2.2	15
7	A Role for Adipocytes and Adipose Stem Cells in the Breast Tumor Microenvironment and Regenerative Medicine. <i>Frontiers in Physiology</i> , 2021, 12, 751239.	2.8	15
8	Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor. <i>PLoS ONE</i> , 2020, 15, e0226464.	2.5	13
9	ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1164.	2.8	13
10	Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ER±-negative Breast Cancers to Tamoxifen through ER± Reexpression. <i>Molecular Cancer Research</i> , 2017, 15, 1491-1502.	3.4	12
11	Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation. <i>Non-coding RNA</i> , 2016, 2, 8.	2.6	11
12	NEK5 activity regulates the mesenchymal and migratory phenotype in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 49-61.	2.5	10
13	Multifunctional profiling of triple-negative breast cancer patient-derived tumoroids for disease modeling. <i>SLAS Discovery</i> , 2022, 27, 191-200.	2.7	7
14	Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation. <i>Journal of Cellular Biochemistry</i> , 2021, 122, 835-850.	2.6	5
15	Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review. <i>Current Medicinal Chemistry</i> , 2021, 28, 6096-6109.	2.4	5
16	Patient-Derived Xenografts as an Innovative Surrogate Tumor Model for the Investigation of Health Disparities in Triple Negative Breast Cancer. <i>Women S Health Reports</i> , 2020, 1, 383-392.	0.8	4
17	Breast Cancer-Stromal Interactions: Adipose-Derived Stromal/Stem Cell Age and Cancer Subtype Mediated Remodeling. <i>Stem Cells and Development</i> , 2022, 31, 604-620.	2.1	3
18	Application of a small molecule inhibitor screen approach to identify CXCR4 downstream signaling pathways that promote a mesenchymal and fulvestrant-resistant phenotype in breast cancer cells. <i>Oncology Letters</i> , 2021, 21, 380.	1.8	1

#	ARTICLE	IF	CITATIONS
19	Liver Kinase B1 Regulates Remodeling of the Tumor Microenvironment in Triple-Negative Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	1
20	A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways. <i>Anti-Cancer Drugs</i> , 2020, 31, 759-775.	1.4	0
21	436 Examining the Role of Obesity and Leptin Signaling in Triple Negative Breast Cancer. <i>Journal of Clinical and Translational Science</i> , 2022, 6, 86-86.	0.6	0